ARRDC3 and breast cancer: While more studies are needed to identify the breast cancer subtypes that are sensitive to SINE compounds, our result suggest that TNBCs that express lower ARRDC3 levels are more sensitive and that SINE compounds can emerge as a therapeutic option for TNBC as a single agent or as part of a combination therapy.